RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo

Gene Therapy

Volumn 12, Issue 5, 2005, Pages 461-466

  Urban Klein, B ^a   Werth, S ^a   Abuharbeid, S ^a   Czubayko, F ^a   Aigner, A ^a  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

Author keywords

Gene targeting; HER 2; PEI; Polyethylenimine; RNAi; siRNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG PENETRATION; DRUG USE; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RNA DEGRADATION; RNA INTERFERENCE; RNA STABILITY; SUBCUTANEOUS TISSUE TUMOR;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE TARGETING; GENE THERAPY; GENES, ERBB-2; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; POLYETHYLENEIMINE; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

MAMMALIA;

EID: 15444373116     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302425     Document Type: Article

References (35)

1. Martinez J et al. Single-stranded antisense siRNAa guide target RNA cleavage in RNAi. Cell 2002; 110: 563-574.
2. Elbashir SM et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
3. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
4. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20 1006-1010.
5. McCaffrey AP et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-644.
6. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438.
7. Coburn, GA, Cullen BR. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002; 76: 9225-9231.
8. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003; 100: 2014-2018.
9. Zhang L et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003; 303: 1169-1178.
10. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
11. Boussif O et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-7301.
12. Aigner A et al. Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Therapy 2002; 9: 1700-1707.
13. Kichler A. Gene transfer with modified polyethylenimines. J Gene Med 2004; 6 (Suppl 1): S3-S10.
14. Wagner E, Kircheis R, Walker GF. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. Biomed Pharmacother 2004; 58: 152-161.
15. Dheur S et al. Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev 1999; 9: 515-525.
16. Bologna JC, Dorn G, Natt F, Weiler J. Linear polyethylenimine as a tool for comparative studies of antisense and short double-stranded RNA oligonucleotides. Nucleosides Nucleotides Nucleic Acids 2003; 22: 1729-1731.
17. Tzahar E et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16: 5276-5287.
18. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
19. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002; 62: 209-243.
20. Bookman MA et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with over-expression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-290.
21. Choudhury A et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108: 71-77.
22. Yang G et al. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004; 279: 4339-4345.
23. Abuharbeid S et al. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun 2004; 321: 403-412.
24. Hsieh SS, Malerczyk C, Aigner A, Czubayko F. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int J Cancer 2000; 86: 644-651.
25. Zaric V et al. Effective polyethylenimine-mediated gene transfer into human endothelial cells. J Gene Med 2004; 6: 176-184.
26. Takei Y et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-3370.
27. Maeda H et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-284.
28. Czubayko F et al. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Therapy 1997; 4: 943-949.
29. Juhl H, Downing SG, Wellstein A, Czubayko F. HER-2/neu is rate-limiting for ovarian cancer growth: Conditional depletion of HER-2/neu by ribozyme targeting. J Biol Chem 1997; 272: 29482-29486.
30. Song E et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351.
31. Filleur S et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003; 63: 3919-3922.
32. Aigner A et al. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 2001; 20: 2101-2111.
33. Aigner A et al. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 2001; 92: 510-517.
34. Aigner A et al. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002; 21: 5733-5742.
35. Aigner A, Ray PE, Czubayko F, Wellstein A. Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem Cell Biol 2002; 117: 1-11.